Staphylococcus albicans bacterial lysate - Qilu Pharmaceutical
Alternative Names: Neisseria bacterial lysate; Staphylococcus albicans bacterial lysateLatest Information Update: 22 Nov 2022
At a glance
- Originator Qilu Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Chronic obstructive pulmonary disease
Most Recent Events
- 05 Jan 2022 Clinical trials in Chronic obstructive pulmonary disease (In the elderly, In adults) in China (PO) (NCT05543343)